SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Incyte (INCY)
An SI Board Since January 1996
Posts SubjectMarks Bans Symbol
3202 131 0 INCY
Emcee:  scaram(o)uche Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2777Chuckle. I get it. Incyte is to Abbott as GLPG0634 is to 110. Made my day, scaram(o)uche-9/17/2012
2776It won’t have any effect on ABT, but it might have some effect on AbbVie.DewDiligence_on_SI-9/17/2012
2775BTW, I've coined the term "Abbott Killer" for 110. :-)scaram(o)uche-9/17/2012
2774Nice nugget, thanks. The more we know, the more we don't know. I was an imscaram(o)uche-9/16/2012
2773interesting as more and more evidence arrises that part of the ovarian cancers dalroi-9/16/2012
2772I'm dizzy. Exciting job, clinical director at incy..... clinicaltrials.govscaram(o)uche-9/15/2012
2771Interesting change to this 110 protocol...... clinicaltrials.gov Implies thatscaram(o)uche-9/12/2012
2770ama-assn.org clinicaltrials.gov <i>This is a dose ranging study to evaluscaram(o)uche-9/11/2012
2769Jakavi® (ruxolitinib) First Medication to Receive European Commission Approtnsaf-8/28/2012
2768If you google incb39110-290, you'll find three links for which the google ghscaram(o)uche-8/3/2012
276729 minutes into the conf. call, Galapagos sensitivity goes to nine on scale of 1scaram(o)uche-8/3/2012
2766Tofacitinib scorecard: siliconinvestor.com If there’s a reason to not approveDewDiligence_on_SI-8/1/2012
2765 Preclinical Genetic Data Support Ongoing Clinical Trials Testing IDO InhibitorsBiomaven-7/19/2012
2764Makes perfect sense [to lower 2Q12 Jakafi forecast] Why, IYO?DewDiligence_on_SI-7/13/2012
2763Huang from Barclays (equal weight) lowers Q2 expectations for Jakafi, $42M to $3scaram(o)uche-7/13/2012
2762Latest results: finance.yahoo.com Look excellent to me - the slope of the curvBiomaven-6/8/2012
2761<i>>Dew pointed out that the de facto standard monotherapy Humira dose DewDiligence_on_SI-6/6/2012
2760>>a DAS28 remission rate of 40 percent with ACTEMRA versus 11 percent withBiomaven-6/6/2012
2759Here's one EULAR-Berlin release that has a nice aside..... finance.yahoo.cscaram(o)uche-6/6/2012
2758Same ballpark as Pfizer's drug in terms of efficacy as measured by ACR20/50/Biomaven-6/6/2012
2757Eular abstract info posted online for LLY/INCY 050 RA Phase 2 b. 12 week Phase quantman-6/6/2012
2756Aside.... by merely participating in this discussion and after the new bmy datscaram(o)uche-6/5/2012
2755Good question.... old paper, but these guys ought to know your answer by now (anscaram(o)uche-6/5/2012
2754Any clue if IDO inhibitor might be complementary with anti-PD-1? PeterBiomaven-6/5/2012
2753Thanks, Sales! Rickscaram(o)uche-6/4/2012
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News